Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Brief Summary: This phase I trial studies the side effects and best dose of genetically modified T-cells following peripheral blood stem cell transplant in treating patients with recurrent or high-risk non-Hodgkin lymphoma. Giving chemotherapy before a stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing the T cells from the donor cells before transplant may stop this from happening. Giving an infusion of the donor's T cells (donor lymphocyte infusion) later may help the patient's immune system see any remaining cancer cells as not belonging in the patient's body and destroy them (called graft-versus-tumor effect)


Options:
A: Arm Label: HIGH DOSE CHEMOTHERAPY AND ASCT; Type: EXPERIMENTAL; Interventions: Drug: Carmustine, Drug: Etoposide, Drug: Cytarabine, Drug: Melphalan, Biological: Pegfilgrastim, Biological: 19-28z T CELLS, Procedure: Autologous Stem Cell Transplantation | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: Pegfilgrastim; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: 19-28z T CELLS; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: PROCEDURE; Name: Autologous Stem Cell Transplantation; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT
B: Arm Label: Tisagenlecleucel+Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab
C: Arm Label: CD19-7×19 CAR-T plus PD1 monoclonal antibody; Type: EXPERIMENTAL; Interventions: Biological: CD19-7×19 CAR-T plus PD1 monoclonal antibody | Intervention Type: BIOLOGICAL; Name: CD19-7×19 CAR-T plus PD1 monoclonal antibody; Assigned to Arm(s): CD19-7×19 CAR-T plus PD1 monoclonal antibody
D: Arm Label: Treatment (genetically modified T cell infusion); Type: EXPERIMENTAL; Interventions: Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Procedure: autologous hematopoietic stem cell transplantation, Other: laboratory biomarker analysis | Intervention Type: BIOLOGICAL; Name: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (genetically modified T cell infusion)

Answer: D